Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
MERS: Progress on the global response, remaining challenges and the way forward

FAO-OIE-WHO MERS Technical Working Group∗ (Ryan Aguannoa, Ahmed Eldrissi, Amgad A. Elkholy, Peter Ben Embarekb, Emma Gardnerc, Rebecca Grantc, Heba Mahrousy, Mamunur Rahman Malikb, Gounalan Pavade, Sophie VonDobschuetza, Lidewij Wiersmaa, Maria D. Van Kerkhoveb))

a Food and Agriculture Organization of the United Nations, Italy 
b Health Emergencies Programme, World Health Organization, Switzerland

c Center for Global Health, Institut Pasteur, France

d World Organization for Animal Health, France

ARTICLE INFO

Keywords: MERS-CoV Research Animal-human interface Dromedary camels Zoonosis Vaccine

ABSTRACT

This article summarizes progress in research on Middle East Respiratory Syndrome (MERS) since a FAO-OIE-WHO Global Technical Meeting held at WHO Headquarters in Geneva on 25–27 September 2017. The meeting reviewed the latest scientific findings and identified and prioritized the global activities necessary to prevent, manage and control the disease. Critical needs for research and technical guidance identified during the meeting have been used to update the WHO R&D MERS-CoV Roadmap for diagnostics, therapeutics and vaccines and a broader public health research agenda. Since the 2017 meeting, progress has been made on several key actions in animal populations, at the animal/human interface and in human populations. This report also summarizes the latest scientific studies on MERS since 2017, including data from more than 50 research studies examining the presence of MERS-CoV infection in dromedary camels.

1. Background: Middle East Respiratory Syndrome

Since its identification in the Kingdom of Saudi Arabia (KSA) (Zaki et al., 2012) and Jordan (Hijawi et al., 2013) in 2012, Middle East Respiratory Syndrome (MERS) has become a global public health threat. Typical of an emerging zoonosis, Middle East respiratory syndrome coronavirus (MERS-CoV) has an animal reservoir, i.e. dromedary camels in which the virus causes little to no disease (Mohd et al., 2016). Many details about the extent of circulation and the mechanisms of transmission within dromedary camel herds, or factors related to zoonotic transmission and differences in circulating MERS-CoV strains, remain unknown. The virus has repeatedly spilled over from dromedary camels to humans, principally in countries on the Arabian Peninsula, causing significant morbidity and mortality (World Health Organization, 2017a; Azhar et al., 2014). Clusters of cases in the community and among family members are rare (World Health Organization, 2017a; Drosten et al., 2014). However, delays in diagnosis in hospitals has sometimes led to secondary cases among health care workers, patients sharing rooms or family members as a result of unprotected direct contact with a patient before isolation. This human-to-human transmission in health care facilities can sometimes be amplified, causing very large outbreaks, as has been seen in the Middle East and in the Republic of Korea, with significant public health and economic impacts (Hijawi et al., 2013; Assiri et al., 2013; Al-Abdallat et al., 2014; Drosten et al., 2015; Al Hosani et al., 2016; Ki, 2015; Park et al., 2015). As of August 2018, more than 2249 human cases from 27 countries have been reported to the World Health Organization (WHO) (World Health Organization, 2017a).

The FAO, OIE and WHO Tripartite have regularly brought together affected member states, public health and animal officials, and academics to discuss what is known and unknown about the zoonotic origin of MERS-CoV (World Health Organization, 2016; FAO, 2016; WHO Regional office for the Eastern Mediterranean, 2013a). The purposes of these meetings and workshops have been to advocate for more surveillance and research on MERS-CoV in animals and humans, to share information about how MERS-CoV is transmitted between animals, from animals to humans and between humans, to describe the diseases it causes, and to develop policies and guidelines for detection,

https://doi.org/10.1016/j.antiviral.2018.09.002

Received 30 August 2018; Accepted 4 September 2018
Available online 17 September 2018

0166-3542/ © 2018 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
reporting of animal and human infections, and prevention of human cases and clusters.

In the two years since the last international technical consultation on MERS-CoV in 2016, there have been notable improvements in surveillance and reporting of human cases, multidisciplinary research, cross-sectoral collaboration at country level, public awareness about the disease, and laboratory and surveillance capacity in affected countries. In addition, a number of countries in the Arabian Peninsula and in Africa have engaged in research activities and surveillance of camel populations to shed light on the wider distribution of this virus or investigate transmission patterns and routes for viral shedding. As a follow-up to previous meetings (World Health Organization, 2016; FAO, 2016, 2014; WHO Regional office for the Eastern Mediterranean, 2014; WHO Regional office for the Eastern Mediterranean, 2013b, 2013c), FAO, OIE and WHO Tripartite held a Global Technical Meeting on MERS-CoV with representatives from Ministries of Health and Ministries of Agriculture, subject matter experts, researchers, funders and industrial partners from 25 to 27 September 2017 in Geneva, Switzerland (see Supplementary Information) (World Health Organization et al., 2017). The objectives were to review the latest scientific evidence on MERS-CoV, further enhance cross-sectoral collaboration and communication during preparedness and response activities, and identify research priorities given the advancements in our knowledge.

With 130 participants, this was the largest MERS-CoV Technical Meeting to date and the first meeting attended by representatives from both affected and at-risk countries. That is, countries which have reported human infection, countries with evidence of MERS-CoV in dromedary camels but no reported human cases, and countries at risk for importation (countries without infected camels that have close ties to affected countries through expatriate workers, travel to affected countries for medical procedures and/or frequent international travel).

2. Findings from the global technical meeting

There is strong consensus among all stakeholders that dromedary camels are the main source of transmission to humans. In 2014, OIE identified MERS-CoV as an emerging disease with zoonotic potential in camels and thereby creating expectations of reporting positive camels by countries (OIE, 2014a) and recently published a MERS-CoV case definition (OIE, 2017) for the reporting of confirmed and suspected infection in camels.

Not all countries face the same risks. For example, countries that have the infected reservoir (dromedary camels) differ from those countries in which dromedary camels show no evidence of current or past infection (Fig. 1). There may also be differences in spillover potential in countries with documented zoonotic transmission, compared to those without, due to several factors including potential differences in husbandry practices, cultural, social, medicinal, occupational exposures, prevalence of underlying chronic medical conditions, or genetic factors in human populations, and MERS-CoV viral differences (Wong et al., 2015). As such, technical and risk mitigation guidance to protect human health and research priorities differ by region.

The findings from the Global Technical Meeting are summarized below:

i. Surveillance needs: Surveillance in animals and humans to limit zoonotic transmission

Routine human surveillance for MERS-CoV in KSA (Abdulaziz et al., 2017) and throughout the Middle East has improved since the identification of the virus in humans in 2012, but there is significant variation in the quality and extent of surveillance between countries. In other parts of the world, surveillance is limited. Since it is known that MERS-CoV is enzootic in areas of Africa and Asia where dromedary camels are found, heightened awareness and surveillance for zoonotic MERS is required. This is currently lacking and remains a knowledge gap.

One exception is the notable effort to identify potential MERS-CoV infection among pilgrims travelling back from the Middle East. Since 2012, event-based surveillance among pilgrims returning from Hajj, Umrah and other religious events in KSA has been conducted by KSA and countries sending pilgrims. While many return reporting respiratory symptoms, no MERS-CoV infections have been identified among returning pilgrims (Muraduzzaman et al., 2018; Barasheed et al., 2014; Atabani et al., 2016; Koul et al., 2017; Anan et al., 2015; Ma et al., 2017; Memish et al., 2014a, 2014b; Refaey et al., 2017; Al-Abdallat et al., 2017; Matthew et al., 2015; Alqahtani et al., 2016; Win et al., 2016; Yavarain et al., 2018; Kapoor et al., 2014).

Among animals, field surveys conducted to date have included several domestic and wildlife species including dromedary camels (Camelus dromedarius) and Bactrian camels (Camelus bactrianus), goats, bats, cattle, sheep, chickens, swine, ducks, buffalo and equids. Field studies in dromedary camels have been conducted in a number of countries (Table 1). To date, MERS-CoV RNA or MERS-CoV-specific antibodies have been identified in dromedary camels a number of countries (Table 1) except Australia (Hemida et al., 2014), Kazakhstan (Miguel et al., 2016), and the Netherlands (Reusken et al., 2013a). Other livestock such as alpacas (Vicugna pacos), llamas (Llama pacos), young goats, rabbits and pigs have been shown to be susceptible to experimental infection (Cramer et al., 2016; Adney et al., 2016; Vergara-Alert et al., 2017).

Despite improvements, routine surveillance in dromedary populations is limited. The lack of surveillance information about MERS-CoV circulation in dromedary camels restricts our understanding of the transmission dynamics and epidemiology in dromedary camel populations. Meeting participants agreed that surveillance should be integrated into existing surveillance systems, particularly in at-risk countries, similar to One Health approaches developed for avian influenza, and existing human respiratory disease surveillance systems set up for influenza-like illness (ILI) or severe acute respiratory infections (SARI).

Currently, a limitation in our ability to mitigate spillover from dromedary camels to humans is a lack of clarity on the mode(s) of transmission between dromedary camels and humans, the extent and epidemiology of MERS-CoV circulation in dromedary camels in large parts of Africa and South Asia, and on why zoonotic transmission is limited across Africa, large parts of the Middle East, and some parts of South Asia despite high seroprevalence in dromedary camels (Chu et al., 2018) (Table 1).

FAO has outlined the meeting participants conclusions on priorities for MERS-CoV surveillance and management of PCR positive dromedary camels, coordinated outbreak investigation of community acquired cases with dromedary exposure, testing of animals at quarantine and entry points, food safety and environmental contamination, risk communication and awareness raising for MERS-CoV among animal owners and intersectoral collaboration and coordination in an updated Doha Declaration first published in 2015 (FAO, 2015) (REF/hyperlink).

In dromedary camels, longitudinal studies to evaluate the natural history, shedding profile and immunity were highlighted as key research priorities. Meeting participants agreed that further understanding of differences in viral strains and transmission dynamics, including the role of immunity in acquiring infection and shedding virus, the geographic range of spillover events, and environmental, behavioral or host-related risk factors for zoonotic transmission should be prioritized.

ii. Research needs: Hospital transmission and infection prevention and control

Countries face significant challenges in the early identification and diagnosis of MERS in humans due to the non-specificity of clinical symptoms (Arabi et al., 2017a; TheS-Coesearch, 2013; Arabi et al., 2017b; Al-Tawfiq et al., 2017; Al-Tawfiq and Hinedi, 2018; Hui et al., ).
The spectrum of illness ranges from no symptoms (or asymptomatic infection) to severe disease including pneumonia, acute respiratory disease syndrome, organ failure and death, with a case fatality ratio of 35.5% among reported cases (World Health Organization, 2012). The delay in identification and recognition of signs and symptoms compatible with MERS and delay in early isolation of patients has reduced the ability to prevent transmission between people in health care settings, notably in emergency departments, cardiac care centers and renal dialysis units (Hijawi et al., 2013; Assiri et al., 2013; Al-Abdallat et al., 2014; Drostén et al., 2015; Al Hosani et al., 2016; Ki, 2015; Park et al., 2015; Ahmed et al., 2018; Amer et al., 2018).

Our understanding of human-to-human transmission in health care settings has improved through experimental and observational studies conducted in countries during such outbreaks. For example, studies of respiratory pathogens (Yu et al., 2007; Tran et al., 2012; Thompson et al., 2013) and MERS-CoV conducted in the Middle East (Assiri et al., 2013; Oboho et al., 2015; Hunter et al., 2016; Balkhy et al., 2016) and the Republic of Korea (Bin et al., 2016; Kim et al., 2016a, 2016b; Nam et al., 2017) illustrate that aerosol-generating procedures and non-invasive ventilation, combined with inappropriate infection prevention and control practices and lack of adherence to standard practices had an important role in facilitating human-to-human transmission in health care settings. The role of environmental contamination has been evaluated in a number of hospitals following the 2015 outbreak in the Republic of Korea and collaborative, experimental studies are being conducted to evaluate the viability and persistence of MERS-CoV on surfaces and in the air (Bin et al., 2016; Kim et al., 2016a; van Doremalen et al., 2013). The role of mild or asymptomatic cases in transmission chains, however, remains unclear (Omrani et al., 2013; Memish et al., 2014c; Al-Gethamy et al., 2015; Moon and Son, 2017; Al-Abdely et al., 2018), warranting targeted epidemiological and clinical studies to be conducted among contacts during outbreaks, especially in health care facilities.

Countries which have reported health care-associated outbreaks have implemented a variety of strategies to improve infection prevention and control and reduce human-to-human transmission in hospitals, including the introduction of a visual triage system prior to entrance to the emergency departments, the restructure of emergency department layouts for better triage of patients with respiratory symptoms, the standardization and training and re-training of infection prevention and control practices at facilities with high hospital staff turnover, and the auditing of health care facilities for adherence to infection prevention and control measures.

iii. Product research and development needs: Clinical management, diagnostics and medical interventions

The WHO R&D Blueprint, a global strategy and preparedness plan that allows the rapid activation of R&D of epidemic pathogens, aims to fast-track the development and use of effective point-of-care diagnostic tests, vaccines and medicines that can be used to save lives and avert large scale crises. Since 2015, MERS-CoV has been included in the annual WHO R&D Blueprint list of prioritized pathogens for accelerated research and development on diagnostics, vaccines and therapeutics (World Health Organization). In addition, MERS-CoV has a specific roadmap for product research and development, outlined by WHO in...
Table 1

Field studies of evidence of MERS-CoV infection in dromedary camels. ppNT: pseudoparticle neutralization; MN: microneutralization; CI: confidence interval; VNT: virus neutralizing antibodies test.

| Country                | Number of camels | Evidence of MERS-CoV infection |
|------------------------|------------------|--------------------------------|
| Australia              | 25               | No evidence for MERS-CoV infection in dromedary camels (Hemida et al., 2014) |
| Bangladesh             | 55               | 17 (31%) samples were seropositive (Arifil et al., 2018) |
| Burkina Faso           | 525              | Seropositivity rates ranged from 73.2% (95% CI: 48.6–88.8) to 84.6% (95% CI: 77.2–89.9) and virus detection from 0% (95% CI: 0–0) to 12.2% (95% CI: 7–20.4) (Miguel et al., 2017) |
| Egypt                  | 2825             | Of 2825 nasal swabs, RNA detection rate was 15% by RT-PCR. Of 2541 sera samples, the overall seroprevalence was 71% (Ali et al., 2017) |
|                       | 324              | Of 1078 nasal swab specimens tested positive for presence of MERS-CoV RNA. Antibodies against MERS-CoV were detected in 48 (92.3%) of 52 serum samples (ref 48) (Chu et al., 2014) |
|                       | 110              | Of 1031 serological tests, 871 (84.5%) had MERS-CoV neutralizing antibodies (Ali et al., 2015) |
|                       | 110              | 4 (3.6%) nasal swab specimens tested positive for presence of MERS-CoV RNA. Antibodies against MERS-CoV were detected in 48 (92.3%) of 52 serum samples (ref 48) (Chu et al., 2014) |
|                       | 110              | 103 (93.6%) sera collected neutralized MERS-CoV using ppNT (Perera et al., 2013b) |
|                       | 43               | 34 (79.1%) dromedary camels were positive for MERS-CoV antibodies using MN (Shuller MX et al., 2014) |
|                       | 632              | Seropositivity rates ranged from 85.1% (95% CI: 71.8–92.7) to 94.9% (95% CI: 95.4–99.9) and the viral RNA detection rates from 0% (95% CI: 0–0) to 15.7% (95% CI: 8.2–28.0) (Miguel et al., 2016) |
|                       | 188              | Seropositivity was 93% in adult dromedary camels and 97% for juvenile dromedary camels (Chantal et al., 2014) |
|                       | 11               | Neutralizing antibodies to MERS-CoV were found in all sera from dromedary camels (Reusken et al., 2013c) |
|                       | 45               | 42 nasal swabs tested positive for the presence of MERS-CoV nucleic acid (van Doremalen et al., 2017) |
|                       | 455              | No evidence for MERS-CoV infection in dromedary camels (Miguel et al., 2016) |
|                       | 774              | 228 (29.5%) were positive using rELISA test (Gorman et al., 2014) |
|                       | 335              | Seroprevalence of MERS-CoV antibodies in the sampled population was 46.9% (95% CI: 41.4–52.5) (Deem et al., 2015) |
|                       | 203              | 150 (74%) samples were positive for the presence of MERS-CoV RNA (Falzarano et al., 2017) |
|                       | 1309             | 158 (12.1%) nasal swabs were positive for MERS-CoV (Sabir et al., 2014) |
|                       | 698              | The overall prevalence of MERS infection in camels in animal markets and slaughterhouses by rRT-PCR was 56.4% (Ali et al., 2015) |
|                       | 99               | High levels of seropositivity in two herds demonstrated – in one herd, all samples had MERS-CoV antibodies (Hemida et al., 2017) |
|                       | 310              | 280 (90.3%) samples were positive using ppNT (Hemida et al., 2013) |
|                       | 171              | 144 (84.2%) sera samples had specific antibodies against MERS-CoV (Harrath and Abu Dudier, 2018) |
|                       | 9                | 2 (22.2%) nasal samples were positive using RT-PCR (Ziad et al., 2014) |
|                       | 9                | 1 (11.1%) nasal samples were negative for MERS-CoV RNA. All serum samples had high titers of MERS-CoV antibodies (Azhar et al., 2014) |
|                       | 131              | 118 (90.1%) had detectable ppNT antibody titres to MERS-CoV (Hemida et al., 2014) |
|                       | 131              | archived sera |
|                       | 118              | No evidence for MERS-CoV infection in dromedary camels (Hemida et al., 2014) |
|                       | 63               | 5 (7.9%) nasal samples were positive using RT-PCR (WAHIS Interface, 2014) |
|                       | 570              | 502 (88.1%) were positive for antibodies against MERS-CoV (Falzarano et al., 2017) |
|                       | 343              | Seropositivity rates ranged from 48.3% (95% CI: 18.3–79.5) to 100% (95% CI:100-100) and viral RNA detection rates from 0% (95% CI: 0–0) to 7.6% (95% CI: 1.9–26.1) (Miguel et al., 2016) |
|                       | 358              | Seropositivity was 94% in adult dromedary camels and 93% for juvenile dromedary camels (Chantal et al., 2014; Chu et al., 2015) |
|                       | 132              | 14 (11%) nasal swabs were positive using RT-qPCR (Chantal et al., 2014; Chu et al., 2015) |
|                       | 2529             | MERS-CoV RNA was detected in 4/38 (10.5%) of camels aged < 2 years, in 31/1400 (2.2%) aged 2–4 years and in 20/1091 (1.8%) aged > 4 years (So et al., 2018) |
|                       | 76               | 5 (6.6%) proved positive in all applied RT-qPCR and RT-PCR assays. (Nowotny and Kolodziejek, 2014) |
|                       | 50               | 50 (100%) had protein-specific antibodies against MERS-CoV (Reusken et al., 2013a) |
|                       | 565              | 315 (55.8%) samples exceeded the ELISA signal cutoff. Of these, 223 (39.5%) were confirmed using MN (Saqib et al., 2017) |

(continued on next page)
Table 1 (continued)

| Country                        | Number of camels | Evidence of MERS-CoV infection |
|-------------------------------|------------------|--------------------------------|
| Qatar                         | 14               | 3 (21.4%) nasal samples were positive by RT-PCR [Haagmans et al., 2014] |
|                               | 105              | 62 (59.0%) camels showed evidence for virus shedding in at least one type of swab at the time of slaughter [Farag et al., 2015] |
|                               |                  | Antibodies to MERS-CoV S1 were found in 100 of 103 (97.1%) dromedary camels tested by micro-array technology [Farag et al., 2015] |
|                               |                  | 53 (1.0%) nasal swab had full viral genome isolated [Raj et al., 2014] |
|                               |                  | 33 (2.1%) showed evidence for active virus shedding and 5 (15.2%) had viral RNA in camel milk [Reusken et al., 2014] |
|                               |                  | 10 (90%) sera samples had MERS-CoV-specific antibodies. All nasal swab specimens were negative by PCR [Chantal et al., 2016] |
| Spain (Canary Islands)         | 105              | 15 (14%) had protein-specific antibodies against MERS-CoV [Reusken et al., 2013d] |
| Somalia                       | 86               | 25 (87.5%) dromedary camels were positive for MERS-CoV antibodies using MN [Müller MA et al., 2014] |
| Sudan                         | 60               | 49 (81.7%) dromedary camels were positive for MERS-CoV antibodies using MN [Müller MA et al., 2014] |
| Tunisia                       | 204              | Seropositivity was 30% for animals ≤ 2 years of age and 54% for adult dromedary camels [Chantal et al., 2014] |
| UAE                           | 1113             | 42 (3.7%) nasal swabs yielded positive results [Muhairi et al., 2016] |
|                               | 843              | 786 (93.2%) sera samples were positive for antibodies against MERS-CoV [Sung Sup et al., 2015] |
|                               |                  | 11 (91.8%) sera samples were positive for antibodies supported by similar results in a MERS-CoV recombinant partial spike protein antibody ELISA [Alexandersen et al., 2014] |
|                               |                  | 651 (97.1%) had antibodies against MERS-CoV [Meyer et al., 2014] |
|                               |                  | 376 (28.7%) nasopharyngeal samples positive for MERS-CoV [Li et al., 2017] |
|                               |                  | 254 (92.1%) sera samples were positive for MERS-CoV IgG [Sung Sup et al., 2015] |
|                               |                  | 6 (100%) nasopharyngeal swabs tested positive for MERS-CoV [Paden et al., 2014] |

2015 [Modjarrad et al., 2016]. Recent updates on product research and development, presented at the Global Technical Meeting, are below.

2.2. Vaccines for humans

WHO has identified target product profiles for MERS-CoV vaccines which include a dromedary camel vaccine for the reduction of zoonotic transmission, a human vaccine for long term protection of high risk individuals, such as those working with infected dromedary camels or health care workers, and a human vaccine for reactive use in outbreak settings [World Health Organization, 2017b].

Currently, no MERS-CoV-specific or licensed human vaccines are available [Modjarrad et al., 2016; World Health Organization, 2017c]. Several human vaccine candidates for coronaviruses, including MERS-CoV, are at various stages of development and five general vaccine technology platforms have been developed and target the MERS-CoV spike protein [Modjarrad et al., 2016; Okba et al., 2017]. WHO, the Ministry of Health in KSA and the International Vaccine Institute (IVI) have continued to further align efforts to develop coronavirus vaccines [Excler et al., 2016] and the Coalition for Epidemic Preparedness and Innovation (CEPI) has included MERS-CoV as one of three priority pathogens for financing of a human vaccine. Understanding correlates for protection and having a reliable animal model remain essential for evaluating coronavirus vaccine candidates, including MERS-CoV.

2.3. Vaccines for camels

There was a clear call from Global Technical Meeting participants to accelerate the development of a dromedary camel vaccine in order to evaluate the potential to reduce spillover transmission to humans. The acceptability, cost-effectiveness and feasibility of a dromedary camel vaccine will also need to be evaluated and compared to other intervention strategies, such as human vaccination of high risk groups (e.g., those with occupational exposure). Because MERS-CoV is endemic in dromedary camel populations in the Middle East and elsewhere, multiple intervention strategies, including personal protective measures and the strategic implementation of a camel vaccine, are likely needed to reduce transmission from dromedary camels to humans.
Table 2
List of prioritized research and progress on MERS-CoV research, as discussed at the September 2017 meeting. *Based on an enhanced understanding of the virus, the Doha Declaration (FAO, 2015) is undergoing revision with a focus on guiding surveillance techniques, management of dromedary camels shedding the virus, research, regional and inter-sectoral coordination, risk communication, food and environmental safety practices, and biosecurity measures. The update includes explicit guidance on import testing, quarantine procedures, and management of shedding animals. These recommendations and priority actions in the Doha Declaration will be delivered as a separate document after validation by stakeholders in affected and at risk countries.

| Population focus                   | Prioritized research*                                                                 | Progress since the September, 2017 Meeting                                                                                                                                 |
|-----------------------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| In dromedary camel populations*    | • Conduct natural history studies and evaluate evidence of re-infection              | • The report “MERS-CoV at the Animal-Human Interface – An Update of the 2015 Doha Declaration” published outlining priority actions in surveillance, testing of animals at quarantine and entry points, management of PCR positive dromedary camels, coordinated outbreak investigation of community acquired cases with dromedary exposure, food safety and environmental contamination, risk communication and awareness raising for MERS-CoV among animal owners and intersectoral collaboration and coordination |
|                                   | • Conduct value chain and production system analyses                                 | • Repeat cross-sectional and cohort surveillance studies ongoing in dromedary camels in Jordan, Egypt, Ethiopia, Kenya.                                                                                                                   |
|                                   | • Improve surveillance to evaluate seasonal/temporal variation, if any, in camel viral shedding | • FAO protocol on repeat cross-sectional and cohort surveillance studies dromedary camels available upon request.                                                                                                                     |
|                                   | • Identify critical points for interventions and interruption of within species and zoonotic transmission | • Camel value chain analysis ongoing in Jordan, Egypt, Ethiopia, Kenya.                                                                                                                                                       |
|                                   | • Accelerate the development of vaccine candidates                                    | • WHO-IVI Joint Workshop on MERS-CoV human and dromedary vaccines, 26–27 June 2018 Seoul, Korea.                                                                                                                              |
| At the animal-human interface      | • Map virus circulation and geographic range of MERS-CoV in humans and dromedary camels | • Review of camel/human field study methodology (WHO-Protocol and questionnaires available: Cross-sectional seroepidemiologic study of MERS-CoV infection in high-risk population in contact with dromedary camels) published |
|                                   | • Evaluate geographic extent of spillover to humans in Africa, the Middle East and South Asia | • Camel/human field studies are ongoing or planned in Algeria, Egypt, Ethiopia, Kenya, Mauritania, Niger, Pakistan and Sudan.                                                                                                      |
|                                   | • Conduct animal/human serological and virological studies in specific locations to evaluate risk factors for human infection and exact routes of zoonotic transmission, including food/oral routes, if any | • Protocol developed: Anthropological study to describe and general population contact patterns with dromedary camels (WHO protocol available upon request: Multi-site study to describe frequency and patterns of contact with dromedary camels, and assess other potential and known risk factors for MERS-CoV infection |
|                                   | • Conduct social science and anthropological studies to describe and quantify exposures to dromedary camels and identify opportunities for risk-mitigating interventions | • National and sub-national Rapid-response team training involving human and animal health sectors developed and implemented in several at risk countries in the Middle East and Africa |
| In human populations               | • Accelerate the research, development, implementation and evaluation of medical countermeasures to reduce morbidity and mortality associated with MERS | • MERS-CoV Situational Updates provided by FAO and WHO monthly                                                                                                           |
|                                   | • Identify the risk factors for healthcare workers in hospital settings and role of administrative and environmental control for transmission of infection | • WHO-IVI Joint Workshop on MERS-CoV human and dromedary vaccines, 26–27 June 2018 Seoul, Korea.                                                                                                                              |
|                                   | • Understand the role of silent/asymptomatic cases in transmission of infections in humans and whether any specific behaviors may result in human infection from non-human sources | • Funding for development of clinical trial protocols for MERS treatment and vaccines received and protocols in development in consultation with WHO R&D Blueprint and affected member states |
|                                   | • Conduct targeted epidemiological studies in clinical settings to better understand immune response and duration of infectiousness | • Country workshops held to integrated MERS-CoV preparedness and response plans into larger national respiratory disease preparedness and response plans                                             |
|                                   | • Integrate testing for MERS-CoV into existing respiratory disease surveillance systems to identify extent and spectrum of mild infection in the community | • MERS-CoV virus persistence studies ongoing under experimental conditions                                                                                                             |
|                                   |                                                                                       | • Protocol developed (available upon request) to provide guidance on the collection of surface samples to evaluate MERS-CoV persistence in hospital settings where MERS patients are treated |
At least two promising camel vaccine candidates are currently in development and being evaluated in field trials (Haagmans et al., 2016; Alharbi et al., 2017). Stakeholders agreed that the current funding mechanisms need to include risk-mitigating options that target the animal-human interface to prevent zoonotic transmission. These funding pathways would enable the development of camel vaccine candidates. Stakeholders also agreed that prior to camel vaccine implementation, consultation with camel owners and government agencies, feasibility studies including exploring opportunities for commercial manufacturing and incentives for camel vaccination and an assessment of potential trade implications, would all be critical.

In June 2018, WHO and the International Vaccine Institut (IVI) held a joint workshop update the status of human and animal MERS-CoV vaccine development, and identify and prioritize activities to accelerate vaccine research and development. The meeting was held in Seoul, Korea on 26–27 June and included 120 experts and professionals from industry, academia, international organizations and government agencies around the world, including the Coalition for Epidemic Preparedness Innovations (CEPI), the Korean Ministry of Food and Drug Safety (KMFDS) and the Korea Centers for Disease Control and Prevention (KCDC).

3. The way forward

The Global Technical Meeting served as an opportunity to review the available evidence and best practices for control of this epidemic threat six years after the virus was first detected in humans. This covered our understanding of the virus, our ability to detect and respond to cases in animal and human populations, how we communicate our findings and how our work impacts policy decisions to protect animals and prevent human infections.

During the Global Technical Meeting, the latest findings from scientific studies and knowledge gained from collaborative research and surveillance were shared across animal, environmental and human sectors. FAO, OIE and WHO strongly believe that to effectively address zoonoses, including MERS-CoV, a One Health approach to prevent, detect, contain, eliminate and respond to animal and public health risks from zoonotic high threat respiratory pathogens such as MERS-CoV and should involve all relevant sectors, the public and animal health and academic research community, industry and affected communities. We acknowledged the progress that has been made, and importantly, discussed the challenges that need to be addressed so that we can minimize the future public health and economic impacts of this epidemic prone virus. Our aim was to articulate a clear action plan to address these remaining unknowns and to foster better collaboration between sectors and with subject matter experts willing to support member states.

Given the marked expansion in research related to MERS-CoV conducted in the past two years, FAO, OIE and WHO agree that global surveillance and research activities must now be focused on achieving the following major public health goals: reducing zoonotic transmission, detecting and identifying suspected cases early, providing safe and effective treatment to reduce human morbidity and mortality, and significantly reducing human-to-human transmission in health care settings.

The critical needs for research and technical guidance identified during the Global Technical Meeting have been used to inform the WHO R&D MERS-CoV Roadmap (Modjarrad et al., 2016) and a broader Research Agenda for MERS-CoV and other high threat coronaviruses. This research agenda serves as a catalyst to focus, align and mobilize partners to address outstanding knowledge gaps in relation to MERS-CoV across five technical areas:

i) virus origin and characteristics,
ii) epidemiology and transmission,
iii) clinical management and infection prevention and control,
iv) product development and implementation (Modjarrad et al., 2016) and
v) impact of interventions and operational research. The meeting identified a large number of remaining priorities and the organizing committee has summarized the main research needs in Table 2.

Now is the time to devote more effort to long term planning for MERS-CoV. We believe more focused efforts in our activities and investments to address scientific and public health research questions, accelerate promising medical interventions and are more strategic on where activities are conducted globally will go further to address remaining public health unknowns. While there have been improvements in the ability to prevent human-to-human transmission once a MERS case is identified, these are not sufficient to prevent a large event with substantial public health and economic consequences.

Competing financial interests

The authors have no competing financial interests.

Acknowledgements

We gratefully acknowledge the input from all those who attended the FAO-OIE-WHO Global Technical Meeting on MERS-CoV in September 2017. The authors also thank Malik Peiris for his review of the final manuscript. The opinions expressed in this article are those of the authors and do not necessarily reflect those of the institutions or organizations with which they are affiliated.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/mmcdoino.

References

Abdulaziz, A.B.S., Glen, R.A., Abdullah, G.A., et al., 2017. Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015–February 2016. Emerg. Infect. Dis. J. 23, 682.
Adney, D.R.-O.H., Hartwig, A.E., Bowen, R.A., 2016. Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in camels. Emerg. Infect. Dis. 22, 1031–1037. https://doi.org/10.3201/22061600192.
Ahmed, A.E., Al-Jahdali, H., Alshbuki, A.N., et al., 2018. Early identification of pneumonia patients at increased risk of Middle East respiratory syndrome coronavirus infection in Saudi Arabia. Int. J. Infect. Dis. 79, 51–56.
Al Hosani, F., Pringle, K., Al Mulla, M., et al., 2016. Jll. Response to emergence of Middle East respiratory syndrome coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014. Emerg. Infect. Dis. 22 (7), 1162–1168. https://doi.org/10.3201/eid2207.160940. 2016/22.
Al-Abdallat, M.M., Payne, D.C., Alqasrawi, S., et al., 2014. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus; a serologic, epidemiologic, and clinical description. Clin. Infect. Dis. 59, 1225–1233.
Al-Abdallat, M.M., Rha, B., Alqasrawi, S., et al., 2017. Acute respiratory infections among returning Hajj pilgrims—Jordan, 2014. J. Clin. Virol. 89, 34–37.
Al-Abdely, H.M., Midgley, C.M., Alkhams, A.M., et al., 2018. Infectious MERS-CoV isolated from a mildly ill patient, Saudi Arabia. Open Infect. Dis. 5, e0111–e011.
Al-Dorzi, H.M., Aldawood, A.S., Khan, R., et al., 2016. The critical care response to a hospital outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: an observational study. Ann. Intensive Care 6, 101.
Al-Gethamy, M., Corman, V.M., Hussain, R., Al-Tawﬁq, J.A., Drosten, C., Memish, Z.A., 2015. A case of long-term excretion and subclinical infection with Middle East respiratory syndrome coronavirus in a healthcare worker. Clin. Infect. Dis. 60, 973–974. https://doi.org/10.1093/cid/ciu135. Epub 2014 Dec 16.
Al-Tawﬁq, J.A., Hinedi, K., 2018. The calm before the storm: clinical observations of Middle East respiratory syndrome (MERS) patients. J. Chemother. 30, 179–182.
Al-Tawﬁq, J.A., Alfaraj, S.H., Altuwaijri, T.A., Memish, Z.A., 2017. A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia. J. Infect. 75, 378–379.
Alaglini, A.N., Brise, T., Mishra, N., et al., 2014. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 5 (2) (2014). Web. Alexander, C., Kohberger, G.P., Soule, G., Wernery, U., 2014. Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transboundary Emerg. Dis. 61, 105–108.
Alharbi, N.K., Padron-Regalado, E., Thompson, C.P., et al., 2017. ChaAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine 35, 3780–3788.
Ali M, El-Shesheny R, Kandell A, et al., Cross-sectional surveillance of Middle East
Antiviral Research 159 (2018) 35–44

Reusken, C.B., Haagmans, B.L., Müller, M.A., et al., 2013a. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 13, 701–705. https://doi.org/10.1016/S1473-3099(13)60050-6. [Epub ahead of print].

Reukven, C., Mou, H., Godeke, G.J., et al., 2013b. Specific serology for emerging human coronaviruses by protein microarray. Euro Surveill. 18. pii: 20574. https://doi.org/10.2649/EU.130621.131746.

Mehrzad Ehsan Firoozabadi, F. Aguanno et al.

Mehrdad Ehsan Firoozabadi, F. Aguanno et al.

Mehrdad Ehsan Firoozabadi, F. Aguanno et al.

Mehrdad Ehsan Firoozabadi, F. Aguanno et al.

Mehrdad Ehsan Firoozabadi, F. Aguanno et al.

Mehrdad Ehsan Firoozabadi, F. Aguanno et al.
World Health Organization. Summary report on the International scientific meeting on
Middle East respiratory syndrome coronavirus (MERS-CoV). WHO Regional Office for
the Eastern Mediterranean. Available at: http://applications.emro.who.int/docs/IC_-
Meet_Rep_2016_EN_14725.pdf?ua=1. 2016.

World Health Organization, 2017a. Middle East Respiratory Syndrome Coronavirus
(MERS-cov). Available at: http://www.who.int/emergencies/mers-cov/en/.

World Health Organization, May 2017b. WHO Target Product Profiles for MERS-cov
Vaccines. Available at: http://www.who.int/blueprint/what/research-
development/MERS_CoV_TPP_15052017.pdf?ua=1. 2017.

World Health Organization, 2017c. Landscape Analysis of MERS-cov Research and Project
Development for Diagnostics, Therapeutics and Preventives. Available at: http://
www.who.int/blueprint/priority-diseases/key-action/mers-landscape.pdf?ua=1.

World Health Organization, Food and Agriculture Organization of the United Nations,
World Organisation for Animal Health, 2017. Press Release: Countries Agree Next
Steps to Combat Global Health Threat by MERS-cov. Available at: http://www.who.
int/emergencies/mers-cov/accelerating-response/en/.

Yavarian, J.S.J.N., Naseri, M., Hemmati, P., Dadras, M., Gouya, M.M., Mokhtari Azad, T.,
2018 Jan - Feb. Influenza virus but not MERS coronavirus circulation in Iran, 2013-
2016: comparison between pilgrims and general population. Trav. Med. Infect. Dis.
21 2018;21.

Yu, I.T., Xie, Z.H., Tsai, K.K.C.Y., Lok, S.W., Tang, X.P., Hui, D.S., Lee, N., Li, Y.M., Huang,
Z.T., Liu, T., Wong, T.W., Zhong, N.S., Sung, J.J., 2007. Why did outbreaks of severe
acute respiratory syndrome occur in some hospital wards but not in others? Clin.
Infect. Dis. 44, 1017–1025 Epub 2007 Mar 9.

Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., 2012.
Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl.
J. Med. 367, 1814–1820.

Ziad, A.M., Matthew, C., Benjamin, M., et al., 2014. Human infection with MERS cor-
onavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. J.
20, 1012.